C
Chris Parker
Researcher at Institute of Cancer Research
Publications - 479
Citations - 35757
Chris Parker is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Prostate cancer & Radiation therapy. The author has an hindex of 79, co-authored 422 publications receiving 30260 citations. Previous affiliations of Chris Parker include The Royal Marsden NHS Foundation Trust & University of Toronto.
Papers
More filters
Journal ArticleDOI
Information for decision making by patients with early-stage prostate cancer: a comparison across 9 countries.
Deb Feldman-Stewart,Carlo Capirci,Sarah Brennenstuhl,Christine Tong,Ufuk Abacioglu,Marzena Gawkowska-Suwinska,Francis C. J. M. van Gils,A. Heyda,Sefik Igdem,Víctor Macías,Isabel Monteiro Grillo,Clare Moynihan,Madelon Pijls-Johannesma,Chris Parker,Nuno Pimentel,Herbert Wördehoff +15 more
TL;DR: Although there are country-specific differences in the amount of information required, wide variation within each country suggests that information that patients feel is essential or desired for DM should be addressed on an individual basis in all countries.
Journal ArticleDOI
Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial
Chris Parker,Matthew R. Sydes,Malcolm David Mason,Noel W. Clarke,Daniel M. Aebersold,Johann S. de Bono,David P. Dearnaley,Alastair W. S. Ritchie,J. Martin Russell,George N. Thalmann,Mahesh K. B. Parmar,Nicholas D. James +11 more
TL;DR: The STAMPEDE trial will investigate whether treatment against the primary tumour might indeed retard metastatic progression and thereby prolong survival by testing the role of RT-to-the-prostate in men presenting with metastatic disease.
Journal ArticleDOI
A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer
Shea P. Connell,Marcel Hanna,Frank McCarthy,Rachel Hurst,Martyn Webb,Helen Curley,Helen Walker,Robert D. Mills,Richard Y. Ball,Martin G. Sanda,Kathryn L. Pellegrini,Dattatraya Patil,Antoinette S. Perry,Jack A. Schalken,Hardev Pandha,Hayley C. Whitaker,Nening Dennis,Christine Stuttle,Ian G. Mills,Ian G. Mills,Ian G. Mills,Ingrid Jenny Guldvik,Chris Parker,Daniel Brewer,Daniel Brewer,Colin Cooper,Jeremy Clark +26 more
TL;DR: In this paper, a LASSO-based continuation ratio model was built to generate four prostate urine risk signatures for predicting the probability of normal tissue (PUR), D'Amico low risk, intermediate risk, and high risk prostate cancer.
Journal ArticleDOI
Active surveillance: an individualized approach to early prostate cancer.
TL;DR: Active surveillance aims to individualize the management of early prostate cancer by selecting only those men with significant cancers for curative treatment, and involves close monitoring with early, radical treatment in those with evidence of significant biochemical or histological progression.
Journal ArticleDOI
A population-based study of prostate cancer chemotherapy.
TL;DR: A population-based study to assess variation in the use of prostate cancer chemotherapy over time in a UK cancer network found no change in patterns of care over time.